Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 108.80
Bid: 108.80
Ask: 109.00
Change: -1.00 (-0.91%)
Spread: 0.20 (0.184%)
Open: 109.60
High: 110.00
Low: 108.80
Prev. Close: 109.80
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday tips round-up: Cadbury, Next, Premier Oil

Wed, 06th Jan 2010 06:32

Cadbury shares might rise further in what could be a long, drawn-out takeover battle but the risks appear to be increasingly on the downside, the Telegraph suggests.Irene Rosenfeld, Kraft chief executive, is out to play a slow game and would expect a higher offer to emerge. The million-dollar question is whether it will be a knock-out punch. With the outcome of this takeover battle increasingly uncertain, now is the time for shareholders to cash in, the paper adds.Fashionistas may turn their noses up at the brand, but Next had a storming Christmas, with like-for-like sales in its stores rising by 1.6% over the 22 weeks to December 24, compared with analysts' forecasts of sales being flat to -3%. The company is well-positioned to ride out the rest of the downturn and emerge on the other side in good shape. Profit forecasts were edged up on Tuesday to £490m-£500m for the year to January 31, up from previous guidance of £472m. Hold says the Telegraph.A deal yesterday for Premier Oil to take a 50% stake in Serica Energy's Oates prospect caught the investors' attention and sent Premier's shares up 50p to £12.09. The deal is the latest step in Premier's plan to build a leading player in the central North Sea. Premier trades at a significant discount to its sector, at only 0.75 times risked net asset value, compared with the industry average of 0.93, making the shares a buy, the Times suggests.As the country braces itself for freezing weather, May Gurney, the services company which looks after 37,000 km of the nation's main roads for six county councils, is out with its gritters. Besides councils, May Gurney numbers water companies, Network Rail and the Environment Agency among clients from whom it earns long-term revenues. With £25m of cash on the balance sheet, the hunt is on for bolt-on acquisitions but most of the growth is likely to be organic. Shares have had a good run since the summer, but the quality of earnings suggest there is further to go. Buy says the Times.There is scope for Irish building materials giant CRH to surprise on the upside, particularly if the US performs better than expected. But the shares have enjoyed a good run and are not especially cheap at 12.5 times this year's earnings. Sell says the Independent.The issue for Synchronica, which offers low-cost mobile e-mail services, is one of timing. Synchronica expects the revenue from the contracts it won recently to be recognised in 2009's results but is awaiting the final documentation to update the market further. There could be better times to buy because of nervousness before its impending trading statement and its punchy weighting. Hold for now says the Times.Peat bogs are not an obvious investment choice, but punters with money in the commercial horticulture group William Sinclair, which is also one of the country's biggest peat suppliers, have seen plenty of growth in recent months. But the lack of potential growth would prevent us from being a buyer. If the shares soften, investors should be interested, but sit tight for now. Hold says the Independent.Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.
More News
25 Jun 2024 12:56

IN BRIEF: Syncona Chair & CEO Hollowood buys GBP100,000 in shares

Syncona Ltd - London-based life science investor owns a diversified portfolio of companies spanning across clinical stages - Chair & Chief Executive Officer Chris Hollowood buys 89,588 shares at average price of GBP1.12, worth GBP99,980, in London on Monday.

Read more
20 Jun 2024 12:11

Syncona adds two oncology investments to portfolio

(Sharecast News) - Life science investor Syncona announced the addition of two new oncology companies to its portfolio on Thursday.

Read more
20 Jun 2024 10:22

Syncona swings to annual profit despite challenging market conditions

(Alliance News) - Syncona Ltd on Thursday offered up a resilient set of annual results, swinging to profit after a challenging year thanks in part to the strength of its life sciences portfolio.

Read more
17 Jun 2024 13:15

Syncona to invest GBP40 million into newly created Spur Therapeutics

(Alliance News) - Syncona Ltd on Monday said it will provide further funding to a newly formed firm created after one of its portfolio companies acquired another.

Read more
13 Jun 2024 16:05

UK earnings, trading statements calendar - next 7 days

Friday 14 June 
Tesco PLCTrading Statement
Monday 17 June 
Monks Investment Trust PLCFull Year Results
Tuesday 18 June 
Ashtead Group PLCFull Year Results
Global Smaller Cos Trust PLCFull Year Results
Intercede Group PLCFull Year Results
Oxford BioDynamics PLCHalf Year Results
Tatton Asset Management PLCFull Year Results
Telecom Plus PLCFull Year Results
Wednesday 19 June 
Berkeley Group HoldingsFull Year Results
NextEnergy Solar Fund LtdFull Year Results
Schroder European Real Estate Investment Trust PLCHalf Year Results
Speedy Hire PLCFull Year Results
Severfield PLCFull Year Results
Young & Co's Brewery PLCFull Year Results
Thursday 20 June 
Alpha Financial Markets Consulting PLCFull Year Results
Atrato Onsite Energy PLCHalf Year Results
CMC Markets PLCFull Year Results
Cordiant Digital Infrastructure LtdFull Year Results
DS Smith PLCFull Year Results
Syncona LtdFull Year Results
Urban Logistics REIT PLCFull Year Results
XPS Pensions Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
17 May 2024 14:34

Syncona notes Autolus's first quarter loss widens amid higher costs

(Alliance News) - Syncona Ltd on Friday noted that Autolus Therapeutics PLC reported an increased loss amid higher operating costs.

Read more
9 May 2024 13:58

IN BRIEF: Syncona's Freeline gets positive results for Gaucher disease

Syncona Ltd on Thursday - London-based investor in healthcare companies - Says UK portfolio company Freeline Therapeutics Ltd presents positive new data from its phase I and II Galileo-1 study of FLT201, its novel gene therapy candidate, in Gaucher disease. Says FLT201 demonstrates a favourable safety and tolerability profile, with no infusion reactions and no severe adverse events. Syncona notes that Gaucher disease is a "debilitating genetic disorder caused by a deficiency of the GCase enzyme". Syncona Chief Executive Officer Chris Hollowood says: "We are very encouraged by the data generated from FLT201 which demonstrates a favourable safety and tolerability profile and significant enzyme activity. We are confident this treatment has the potential to challenge the standard of care in Gaucher disease, where current treatments are life-long and do not fully alleviate the disease." Freeline Therapeutics is based in Stevenage, Hertfordshire.

Read more
9 May 2024 11:19

Syncona reports positive findings from investee Freeline

(Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phase one and two study of its gene therapy candidate for Gaucher disease, 'FLT20', showed encouraging results.

Read more
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
11 Apr 2024 14:22

Syncona agrees to sell stake in investee company for GBP7.4 million

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.

Read more
4 Apr 2024 17:06

IN BRIEF: Syncona notes investee Achilles's annual loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.

Read more
14 Mar 2024 14:16

Syncona portfolio company Autolus posts widened loss for 2023

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.

Read more
12 Feb 2024 18:01

IN BRIEF: Freeline shareholders approve Syncona acquisition

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.

Read more
8 Feb 2024 13:45

UPDATE: Syncona portfolio strengthens thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.

Read more
8 Feb 2024 09:41

Syncona portfolio strengthens in third quarter thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.